Menopause and Your Heart
Heart disease is the leading cause of death in women. Risk climbs after menopause, and it climbs quietly. Your cholesterol, blood sugar and waistline can all shift within a few years of your last period, even if nothing else about your life has changed.
Why menopause matters for your heart
Estrogen helps keep blood vessels flexible, helps the liver clear cholesterol, and helps your muscles respond to insulin. When it falls, those protections fade. Women who reach menopause early, before 45, carry higher heart risk for exactly this reason.
Menopause is a good moment to look closely at your numbers. Many of these changes can be measured long before they cause a problem.
What changes, and how hormone therapy affects it
The table below summarizes the research. The arrows show the usual direction of change.
| Marker | What menopause tends to do | What hormone therapy tends to do |
|---|---|---|
| Total cholesterol | ↑ Rises | ↓ Lowers it, more so with estrogen by mouth |
| LDL ("bad") cholesterol | ↑ Rises | ↓ Lowers it, more so with estrogen by mouth |
| HDL ("good") cholesterol | ↓ Falls | ↑ Raises it, more so with estrogen by mouth |
| Triglycerides | ↑ Rise | Patch or gel: neutral or lower. Pill: can raise them |
| Lipoprotein(a) | ↑ May rise | ↓ Modestly lowers it, more so by mouth |
| ApoB (particle count) | ↑ Rises | ↔ Little change |
| Fasting blood sugar | ↑ Rises | ↓ Lowers it |
| Insulin resistance | ↑ Worsens | ↓ Improves |
| Type 2 diabetes risk | ↑ Rises | ↓ Lowers it |
| Belly (visceral) fat | ↑ Increases | ↓ Reduces it |
| Body weight and BMI | ↑ Tends to rise | ↔ Little change |
| Blood pressure | ↑ Often rises | ↔ Neutral or slightly lower |
Pill versus patch or gel
Estrogen taken by mouth passes through the liver first. That gives it a stronger effect on LDL and HDL. But it also raises triglycerides and the clotting proteins the liver makes. Estrogen through the skin, as a patch, gel or spray, skips that first pass. Large observational studies link it to a lower risk of blood clots and stroke than the pill. The right route depends on your labs, your history and your preferences, and it is one of the main things we sort out with you.
Timing matters
For healthy women who start hormone therapy before age 60, or within ten years of their final period, the benefits generally outweigh the risks. Starting much later, after years without estrogen, carries more cardiovascular risk. This is often called the timing hypothesis.
Hormone therapy is prescribed for symptoms like hot flashes, sleep disruption and bone protection. It is not prescribed to prevent heart disease on its own. But its effect on your heart is part of every decision we make about it.
Numbers worth knowing
- Full lipid panel
- ApoB
- Lipoprotein(a), which usually only needs checking once
- Hemoglobin A1c
- Fasting glucose and insulin
- Triglyceride to HDL ratio
- Blood pressure, checked more than once
- Waist measurement at the belly button
- Family history of early heart disease
When estrogen is not a fit
Systemic hormone therapy is generally avoided if you have had a blood clot, stroke or heart attack, an estrogen-sensitive cancer, unexplained vaginal bleeding, or active liver disease. If that is you, there are still effective non-hormonal options for symptoms, and the heart work above matters even more.
- Chest pain, pressure or tightness, or pain spreading to the jaw, back or arm
- Sudden shortness of breath
- Sudden weakness, numbness, facial droop or trouble speaking
- Pain, swelling and warmth in one leg
Women more often have heart attack symptoms that feel like nausea, unusual fatigue, or back or jaw pain. Do not wait it out.
- El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. A Scientific Statement From the American Heart Association. Circulation. 2020;142:e506-e532.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ. 2019;364:k4810.
This page is general education, not medical advice, and it does not replace a visit with your own clinician. Your diagnosis, treatment and any medication instructions come from your individual care plan. Reviewed by Jessica Boggs, MSN, APRN, FNP-C, ENP-C.
5301 Alpha Road, Suite 34, Dallas, TX 75240 · (469) 653-3124 · contact@navarahealthtx.com · navarahealthtx.com
Ready to talk it through?
Bring your questions, your symptoms and your labs. We will go through all of it with you.